サイト内検索


登録済み会員ログイン




未登録の方はこちらから登録できます。
新規会員登録


ご利用案内

ご利用案内


連絡先

TEL.03-5812-5270
FAX.03-3831-0495
E-mail:info@spi-information.com


関連サイト・サービス

市場調査のご依頼、専門分野のイベント・フォーラムの開催などは シード・プランニングにて承っております。

シードプランニング

世界の医療・医薬品産業レポートのデータベースサービスは、sekairyo.comにてご利用いただけます。

sekairyo.com

医療従事者へのあらゆる形態の調査は、メドサークルにお任せ下さい。

メドサークル


セキュリティについて

当サイトのコンテンツ利用時に送信される機密情報は、Verisign認証の元暗号化されて送信されます。


Influenza A Viral Infections Drug Development Pipeline Review, 2018

A型インフルエンザウイルス感染症薬剤開発パイプラインレビュー2018

レポート概要

本レポートは、A型インフルエンザウイルス感染症のパイプライン展望の概要を提供します。 A型インフルエンザH3N2、H1N1、H5N1およびH7N9亜型感染症の治療薬開発に関わる主要な開発企業および治療中の治療薬、休止および中止製品に関する包括的な情報を提供します。

インフルエンザは、主に鼻、喉および気管支に影響を及ぼし、肺にはそれほど一般的に影響を及ぼさない呼吸器の急性感染です。インフルエンザウイルスは、単鎖セグメント化RNAゲノムを有します。それらはOrthomyxoviridaeに属し、それらのコア蛋白質(A、B、C)に基づいて3つの属に分類されます。A型およびB型インフルエンザウイルスは、ヒトにおけるインフルエンザ症例の大半を占めます。

A型インフルエンザウイルスは、2つのウイルス表面蛋白質の発現に基づいてさらに分類することができ、赤血球凝集素(H)、ノイラミニダーゼ(N)が含まれます。これらのウイルスは、突然変異率が高く、ウイルス蛋白質構造が頻繁に変化することが知られています。

■調査範囲

  • 各パイプライン内において、最も活発に活動しているのはどの企業でしょうか?
  • 各適応症において、各開発段階で最も優れた薬物療法的アプローチはどれでしょうか?
  • このパイプライン内において、大学や組織は製薬企業と比べてどの程度重要な役割を果たすでしょうか?
  • この疾患分野において起きた最も重要なR&Dの画期的出来事や、データの公表は何でしょうか?

レポート詳細

目次

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Influenza A Viral Infections Report Coverage
2.2 Influenza A Virus, H3N2 Subtype Infections - Overview
2.3 Influenza A Virus, H1N1 Subtype Infections - Overview
2.4 Influenza A Virus, H5N1 Subtype Infections - Overview
2.5 Influenza A Virus, H7N9 Subtype Infections - Overview

3 Therapeutics Development
3.1 Influenza A Virus, H3N2 Subtype Infections
3.2 Influenza A Virus, H1N1 Subtype Infections
3.3 Influenza A Virus, H5N1 Subtype Infections
3.4 Influenza A Virus, H7N9 Subtype Infections

4 Therapeutics Assessment
4.1 Influenza A Virus, H3N2 Subtype Infections
4.2 Influenza A Virus, H1N1 Subtype Infections
4.3 Influenza A Virus, H5N1 Subtype Infections
4.4 Influenza A Virus, H7N9 Subtype Infections

5 Companies Involved in Therapeutics Development
5.1 Influenza A Virus, H3N2 Subtype Infections
5.2 Influenza A Virus, H1N1 Subtype Infections
5.3 Influenza A Virus, H5N1 Subtype Infections
5.4 Influenza A Virus, H7N9 Subtype Infections

6 Dormant Projects
6.1 Influenza A Virus, H3N2 Subtype Infections
6.2 Influenza A Virus, H1N1 Subtype Infections
6.3 Influenza A Virus, H5N1 Subtype Infections
6.4 Influenza A Virus, H7N9 Subtype Infections

7 Discontinued Products
7.1 Influenza A Virus, H3N2 Subtype Infections
7.2 Influenza A Virus, H1N1 Subtype Infections
7.3 Influenza A Virus, H5N1 Subtype Infections

8 Product Development Milestones
8.1 Influenza A Virus, H3N2 Subtype Infections
8.2 Influenza A Virus, H1N1 Subtype Infections
8.3 Influenza A Virus, H5N1 Subtype Infections
8.4 Influenza A Virus, H7N9 Subtype Infections

9 Appendix
9.1 Methodology
9.2 Coverage
9.3 Secondary Research
9.4 Primary Research
9.5 Expert Panel Validation
9.6 Contact Us
9.7 Disclaimer

1.1 List of Tables
Table 1: Number of Products under Development for Influenza A Virus, H3N2 Subtype Infections
Table 2: Number of Products under Development by Companies Influenza A Virus, H3N2 Subtype Infections
Table 3: Number of Products under Development by Universities/Institutes Influenza A Virus, H3N2 Subtype Infections
Table 4: Products under Development by Companies Influenza A Virus, H3N2 Subtype Infections
Table 5: Products under Development by Universities/Institutes Influenza A Virus, H3N2 Subtype Infections
Table 6: Number of Products under Development for Influenza A Virus, H1N1 Subtype Infections
Table 7: Number of Products under Development by Companies, Influenza A Virus, H1N1 Subtype Infections
Table 8: Number of Products under Development by Universities/Institutes, Influenza A Virus, H1N1 Subtype Infections
Table 9: Products under Development by Companies, Influenza A Virus, H1N1 Subtype Infections
Table 10: Products under Development by Universities/Institutes, Influenza A Virus, H1N1 Subtype Infections
Table 11: Number of Products under Development for Influenza A Virus, H5N1 Subtype Infections
Table 12: Number of Products under Development by Companies, Influenza A Virus, H5N1 Subtype Infections
Table 13: Number of Products under Development by Universities/Institutes, Influenza A Virus, H5N1 Subtype Infections
Table 14: Products under Development by Companies, Influenza A Virus, H5N1 Subtype Infections
Table 15: Products under Development by Universities/Institutes, Influenza A Virus, H5N1 Subtype Infections
Table 16: Number of Products under Development for Influenza A Virus, H7N9 Subtype Infections
Table 17: Number of Products under Development by Companies, Influenza A Virus, H7N9 Subtype Infections
Table 18: Number of Products under Development by Universities/Institutes, Influenza A Virus, H7N9 Subtype Infections
Table 19: Products under Development by Companies, Influenza A Virus, H7N9 Subtype Infections
Table 20: Products under Development by Universities/Institutes, Influenza A Virus, H7N9 Subtype Infections
Table 21: Number of Products by Stage and Target, Influenza A Virus, H3N2 Subtype Infections
Table 22: Number of Products by Stage and Mechanism of Action, Influenza A Virus, H3N2 Subtype Infections
Table 23: Number of Products by Stage and Route of Administration, Influenza A Virus, H3N2 Subtype Infections
Table 24: Number of Products by Stage and Molecule Type, Influenza A Virus, H3N2 Subtype Infections
Table 25: Number of Products by Stage and Target, Influenza A Virus, H3N2 Subtype Infections
Table 26: Number of Products by Stage and Mechanism of Action, Influenza A Virus, H3N2 Subtype Infections
Table 27: Number of Products by Stage and Route of Administration, Influenza A Virus, H3N2 Subtype Infections
Table 28: Number of Products by Stage and Molecule Type, Influenza A Virus, H3N2 Subtype Infections
Table 29: Number of Products by Stage and Target, Influenza A Virus, H5N1 Subtype Infections
Table 30: Number of Products by Stage and Mechanism of Action, Influenza A Virus, H5N1 Subtype Infections
Table 31: Number of Products by Stage and Route of Administration, Influenza A Virus, H5N1 Subtype Infections
Table 32: Number of Products by Stage and Molecule Type, Influenza A Virus, H5N1 Subtype Infections
Table 33: Number of Products by Stage and Target, Influenza A Virus, H7N9 Subtype Infections
Table 34: Number of Products by Stage and Mechanism of Action, Influenza A Virus, H7N9 Subtype Infections
Table 35: Number of Products by Stage and Route of Administration, Influenza A Virus, H7N9 Subtype Infections
Table 36: Number of Products by Stage and Molecule Type, Influenza A Virus, H7N9 Subtype Infections
Table 37: Influenza A Virus, H3N2 Subtype Infections - Pipeline by AbbVie Inc
Table 38: Influenza A Virus, H3N2 Subtype Infections - Pipeline by Adimmune Corp
Table 39: Influenza A Virus, H3N2 Subtype Infections - Pipeline by Aphios Corp
Table 40: Influenza A Virus, H3N2 Subtype Infections - Pipeline by AusBio Ltd
Table 41: Influenza A Virus, H3N2 Subtype Infections - Pipeline by BioCryst Pharmaceuticals Inc
Table 42: Influenza A Virus, H3N2 Subtype Infections - Pipeline by BiondVax Pharmaceuticals Ltd
Table 43: Influenza A Virus, H3N2 Subtype Infections - Pipeline by Cadila Healthcare Ltd
Table 44: Influenza A Virus, H3N2 Subtype Infections - Pipeline by Celltrion Inc
Table 45: Influenza A Virus, H3N2 Subtype Infections - Pipeline by Emergent BioSolutions Inc
Table 46: Influenza A Virus, H3N2 Subtype Infections - Pipeline by FluGen Inc
Table 47: Influenza A Virus, H3N2 Subtype Infections - Pipeline by Inovio Pharmaceuticals Inc
Table 48: Influenza A Virus, H3N2 Subtype Infections - Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd
Table 49: Influenza A Virus, H3N2 Subtype Infections - Pipeline by Johnson & Johnson
Table 50: Influenza A Virus, H3N2 Subtype Infections - Pipeline by Medicago Inc
Table 51: Influenza A Virus, H3N2 Subtype Infections - Pipeline by MedImmune LLC
Table 52: Influenza A Virus, H3N2 Subtype Infections - Pipeline by Mucosis BV (Inactive)
Table 53: Influenza A Virus, H3N2 Subtype Infections - Pipeline by NanoViricides Inc
Table 54: Influenza A Virus, H3N2 Subtype Infections - Pipeline by Novavax Inc
Table 55: Influenza A Virus, H3N2 Subtype Infections - Pipeline by OPKO Health Inc
Table 56: Influenza A Virus, H3N2 Subtype Infections - Pipeline by Sanofi
Table 57: Influenza A Virus, H3N2 Subtype Infections - Pipeline by Sanofi Pasteur SA
Table 58: Influenza A Virus, H3N2 Subtype Infections - Pipeline by Sarepta Therapeutics Inc
Table 59: Influenza A Virus, H3N2 Subtype Infections - Pipeline by SK Chemicals Co Ltd
Table 60: Influenza A Virus, H3N2 Subtype Infections - Pipeline by VBI Vaccines Inc
Table 61: Influenza A Virus, H1N1 Subtype Infections - Pipeline by AbbVie Inc

1.2 List of Figures
Figure 1: Number of Products under Development for Influenza A Virus, H3N2 Subtype Infections
Figure 2: Number of Products under Development by Companies, Influenza A Virus, H3N2 Subtype Infections
Figure 3: Number of Products under Development by Universities/Institutes Influenza A Virus, H3N2 Subtype Infections
Figure 4: Number of Products under Development for Influenza A Virus, H1N1 Subtype Infections
Figure 5: Number of Products under Development by Companies, Influenza A Virus, H1N1 Subtype Infections
Figure 6: Number of Products under Development by Universities/Institutes, Influenza A Virus, H1N1 Subtype Infections
Figure 7: Number of Products under Development for Influenza A Virus, H5N1 Subtype Infections
Figure 8: Number of Products under Development by Companies, Influenza A Virus, H5N1 Subtype Infections
Figure 9: Number of Products under Development by Universities/Institutes, Influenza A Virus, H5N1 Subtype Infections
Figure 10: Number of Products under Development for Influenza A Virus, H7N9 Subtype Infections
Figure 11: Number of Products under Development by Companies, Influenza A Virus, H7N9 Subtype Infections
Figure 12: Number of Products under Development by Universities/Institutes, Influenza A Virus, H7N9 Subtype Infections
Figure 13: Number of Products by Top 10 Targets, Influenza A Virus, H3N2 Subtype Infections
Figure 14: Number of Products by Stage and Top 10 Targets, Influenza A Virus, H3N2 Subtype Infections
Figure 15: Number of Products by Top 10 Mechanism of Actions, Influenza A Virus, H3N2 Subtype Infections
Figure 16: Number of Products by Stage and Top 10 Mechanism of Actions, Influenza A Virus, H3N2 Subtype Infections
Figure 17: Number of Products by Routes of Administration, Influenza A Virus, H3N2 Subtype Infections
Figure 18: Number of Products by Stage and Routes of Administration, Influenza A Virus, H3N2 Subtype Infections
Figure 19: Number of Products by Top 10 Molecule Types, Influenza A Virus, H3N2 Subtype Infections
Figure 20: Number of Products by Stage and Top 10 Molecule Types, Influenza A Virus, H3N2 Subtype Infections
Figure 21: Number of Products by Top 10 Targets, Influenza A Virus, H3N2 Subtype Infections
Figure 22: Number of Products by Stage and Top 10 Targets, Influenza A Virus, H3N2 Subtype Infections
Figure 23: Number of Products by Top 10 Mechanism of Actions, Influenza A Virus, H3N2 Subtype Infections
Figure 24: Number of Products by Stage and Top 10 Mechanism of Actions, Influenza A Virus, H3N2 Subtype Infections
Figure 25: Number of Products by Top 10 Routes of Administration, Influenza A Virus, H3N2 Subtype Infections
Figure 26: Number of Products by Stage and Top 10 Routes of Administration, Influenza A Virus, H3N2 Subtype Infections
Figure 27: Number of Products by Top 10 Molecule Types, Influenza A Virus, H3N2 Subtype Infections
Figure 28: Number of Products by Stage and Top 10 Molecule Types, Influenza A Virus, H3N2 Subtype Infections
Figure 29: Number of Products by Top 10 Targets, Influenza A Virus, H5N1 Subtype Infections
Figure 30: Number of Products by Stage and Top 10 Targets, Influenza A Virus, H5N1 Subtype Infections
Figure 31: Number of Products by Top 10 Mechanism of Actions, Influenza A Virus, H5N1 Subtype Infections
Figure 32: Number of Products by Stage and Top 10 Mechanism of Actions, Influenza A Virus, H5N1 Subtype Infections
Figure 33: Number of Products by Routes of Administration, Influenza A Virus, H5N1 Subtype Infections
Figure 34: Number of Products by Stage and Routes of Administration, Influenza A Virus, H5N1 Subtype Infections
Figure 35: Number of Products by Top 10 Molecule Types, Influenza A Virus, H5N1 Subtype Infections
Figure 36: Number of Products by Stage and Top 10 Molecule Types, Influenza A Virus, H5N1 Subtype Infections
Figure 37: Number of Products by Targets, Influenza A Virus, H7N9 Subtype Infections
Figure 38: Number of Products by Stage and Targets, Influenza A Virus, H7N9 Subtype Infections
Figure 39: Number of Products by Mechanism of Actions, Influenza A Virus, H7N9 Subtype Infections
Figure 40: Number of Products by Stage and Mechanism of Actions, Influenza A Virus, H7N9 Subtype Infections
Figure 41: Number of Products by Routes of Administration, Influenza A Virus, H7N9 Subtype Infections
Figure 42: Number of Products by Stage and Routes of Administration, Influenza A Virus, H7N9 Subtype Infections
Figure 43: Number of Products by Molecule Types, Influenza A Virus, H7N9 Subtype Infections
Figure 44: Number of Products by Stage and Molecule Types, Influenza A Virus, H7N9 Subtype Infections

発刊日

2018/04/30

体裁

PDF / 188ページ

販売価格

3,995USD

発行

GBI Research

備考

※ご請求は、お申込日のTTSレートで円換算し、消費税を加えた金額になります。
※販売価格はシングルユーザーライセンスのものとなります。他のライセンス形態・価格に関しましてはご相談下さい。
※本レポートは、英文です。PDF(電子媒体)での納品となります。
※本レポートは取り寄せとなりますので、申し込みからお届けまで、多少時間が掛かる場合がございます。

関連カテゴリ

疾病別治療・領域別治療

購入・お問い合わせ

このレポートを購入

詳細を問い合わせる


PAGE